James Liu Joins Femasys as Chief Medical Officer

Femasys Inc. has appointed James Liu, M.D., as chief medical officer. The appointment occurs as the company accelerates commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed.

“It is a great pleasure to welcome Dr. James Liu to Femasys as the company’s next chief medical officer,” Femasys Founder, President, and CEO Kathy Lee-Sepsick stated. “With numerous years of clinical and leadership experience at one of the best gynecology programs in the nation and engagements with some of the most prominent women’s health companies, he is well suited to support our accelerated commercialization efforts focused on reproductive health and to support our continued product development efforts in permanent birth control as a previous principal investigator of earlier clinical studies for FemBloc. The Femasys team also extends its deep gratitude to Dr. Edward Evantash for his service and contributions to the company and we look forward to our continued work together.”
 
Liu earned his medical degree from Ohio State University School of Medicine, completed a residency in obstetrics and gynecology at University of Rochester-Strong Memorial Hospital, and undertook a fellowship in Reproductive Endocrinology at University of California, San Diego. Liu is Professor Emeritus at Case Western Reserve University after serving for more than 21 years as chairman, Department of Obstetrics and Gynecology, University Hospital Health System and the chair, Department of Reproductive Biology, Case Western Reserve University. He also was the Division head, Reproductive Endocrinology and Infertility at the University of Cincinnati.

Liu has authored more than 130 publications and held numerous chair appointments for the American College of Obstetrics and Gynecology, and for seven years served on the practice committee for the American Society for Reproductive Medicine. He also has several issued patents, reviewed National Institutes of Health grants, served on the U.S. Food and Drug Administration Advisory Committee, and has participated as a principal investigator on numerous clinical pharmaceutical and medical device trials.

“With a product pipeline and a culture focused on execution of the development and commercialization of differentiated women’s health procedures, Femasys stands apart in the industry,” Liu said. “I’m excited to join the company as it advances a new wave of potentially transformative therapies to meet the many areas of unmet needs for patients specifically in reproductive health.”
 
Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with in-office, accessible solutions, including a lead revolutionary product candidate and U.S. Food and Drug Administration (FDA)-cleared, therapeutic and diagnostic products. Femasys’ FemBloc permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. Femasys’ FemaSeed Intratubal Insemination, an infertility treatment designed to deliver sperm directly where conception occurs, is now FDA-cleared and has received regulatory approval in Canada. The company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the United States, Canada, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. The company’s diagnostic products include FemVue for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv, an endocervical tissue sampler for cervical cancer diagnosis.